Type 1 CALR Mutation Allele Frequency Correlates with CD34/CXCR4 Expression in Myelofibrosis-type Megakaryocyte Dysplasia: A Mechanism of Disease Progression?

Overview

Journal Blood Cancer J

Date 2024 Jan 22

PMID 38253566

Authors

Giovanni Barosi

Rita Campanelli

Paolo Catarsi

Carlotta Abba

Adriana Carolei

Margherita Massa

Robert Peter Gale

Vittorio Rosti

Affiliations

Soon will be listed here.

Citing Articles

Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine.

Tashkandi H, Elbaz Younes I Cancers (Basel). 2024; 16(9).

PMID: 38730632 PMC: 11083661. DOI: 10.3390/cancers16091679.

References

Rosti V, Massa M, Vannucchi A, Bergamaschi G, Campanelli R, Pecci A . The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007; 38(3):280-6. DOI: 10.1016/j.bcmd.2007.01.003. View

Guglielmelli P, Maccari C, Sordi B, Balliu M, Atanasio A, Mannarelli C . Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. Blood Cancer J. 2023; 13(1):21. PMC: 9884661. DOI: 10.1038/s41408-023-00786-x. View

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

Tefferi A, Lasho T, Finke C, Belachew A, Wassie E, Ketterling R . Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014; 28(7):1568-70. DOI: 10.1038/leu.2014.83. View

Ibarra J, Elbanna Y, Kurylowicz K, Ciboddo M, Greenbaum H, Arellano N . Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms. Blood Cancer Discov. 2022; 3(4):298-315. PMC: 9338758. DOI: 10.1158/2643-3230.BCD-21-0144. View

Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A . Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008; 26(8):1920-30. DOI: 10.1634/stemcells.2008-0377. View

Pietra D, Rumi E, Ferretti V, Di Buduo C, Milanesi C, Cavalloni C . Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2015; 30(2):431-8. PMC: 4740452. DOI: 10.1038/leu.2015.277. View

Kim H, Han Y, Jang J, Jung C, Kim S, Kim H . Effects of -Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms. Diagnostics (Basel). 2022; 12(11). PMC: 9689478. DOI: 10.3390/diagnostics12112570. View

Barosi G, Rosti V, Catarsi P, Villani L, Abba C, Carolei A . Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia. 2020; 35(2):468-475. DOI: 10.1038/s41375-020-0926-6. View

10.

El-Khoury M, Cabagnols X, Mosca M, Vertenoeil G, Marzac C, Favale F . Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. Oncogene. 2020; 39(31):5323-5337. DOI: 10.1038/s41388-020-1368-3. View

11.

Barosi G, Rosti V, Gale R . Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives. Leukemia. 2023; 37(4):725-727. PMC: 10079530. DOI: 10.1038/s41375-023-01861-9. View

12.

Benlabiod C, da Costa Cacemiro M, Nedelec A, Edmond V, Muller D, Rameau P . Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. Nat Commun. 2020; 11(1):4886. PMC: 7522233. DOI: 10.1038/s41467-020-18691-3. View

13.

Wang Y, Chen Y, Lai Y, Wang M, Chen Y, Wu Y . Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 -Mutated MPN. Int J Mol Sci. 2023; 24(10). PMC: 10217897. DOI: 10.3390/ijms24108747. View

14.

Barosi G, Campanelli R, Massa M, Catarsi P, Carolei A, Abba C . Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype. Acta Haematol. 2022; 146(1):14-25. DOI: 10.1159/000527284. View